CL2015000072A1 - Azaindole-derived compounds, pi3k inhibitors; Preparation method; pharmaceutical composition; pharmaceutical combination; and its use for the treatment of immunological disorders, cancer and cardiovascular diseases. - Google Patents

Azaindole-derived compounds, pi3k inhibitors; Preparation method; pharmaceutical composition; pharmaceutical combination; and its use for the treatment of immunological disorders, cancer and cardiovascular diseases.

Info

Publication number
CL2015000072A1
CL2015000072A1 CL2015000072A CL2015000072A CL2015000072A1 CL 2015000072 A1 CL2015000072 A1 CL 2015000072A1 CL 2015000072 A CL2015000072 A CL 2015000072A CL 2015000072 A CL2015000072 A CL 2015000072A CL 2015000072 A1 CL2015000072 A1 CL 2015000072A1
Authority
CL
Chile
Prior art keywords
azaindole
cancer
preparation
treatment
cardiovascular diseases
Prior art date
Application number
CL2015000072A
Other languages
Spanish (es)
Inventor
Edcon Chang
Wolfgang Reinhard Ludwig Notz
Michael B Wallace
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2015000072A1 publication Critical patent/CL2015000072A1/en

Links

CL2015000072A 2013-07-10 2015-01-09 Azaindole-derived compounds, pi3k inhibitors; Preparation method; pharmaceutical composition; pharmaceutical combination; and its use for the treatment of immunological disorders, cancer and cardiovascular diseases. CL2015000072A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361670116P 2013-07-10 2013-07-10

Publications (1)

Publication Number Publication Date
CL2015000072A1 true CL2015000072A1 (en) 2015-10-23

Family

ID=57232488

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000072A CL2015000072A1 (en) 2013-07-10 2015-01-09 Azaindole-derived compounds, pi3k inhibitors; Preparation method; pharmaceutical composition; pharmaceutical combination; and its use for the treatment of immunological disorders, cancer and cardiovascular diseases.

Country Status (1)

Country Link
CL (1) CL2015000072A1 (en)

Similar Documents

Publication Publication Date Title
CL2014002873A1 (en) Compounds derived from pyrimidin-amine or triazin-amine, adn-pk inhibitors; pharmaceutical composition; and its use for the treatment of cancer.
CL2014000543A1 (en) Compounds derived from amino substituted imidazopyridazines, kinase inhibitors, mknk2; Preparation method; intermediary compounds and their use; pharmaceutical composition; pharmaceutical combination; and its use for the treatment of cancer.
BR112016000489A2 (en) compound, pharmaceutical composition comprising it, use of the composition and methods for making compounds
BR112015031475A2 (en) compound, pharmaceutical composition, method for treating a disease or condition, kit, and use of compound.
CL2016002735A1 (en) Imidazo [4,5-c] quinolin-2-one compounds and their use to treat cancer
CL2014001103A1 (en) Compounds derived from heteroaryl pyridone and substituted aza-pyridone, btk kinase inhibitors; pharmaceutical composition that includes them; process of preparation of the pharmaceutical composition; pharmaceutical kit; and use for the treatment of immune disorders, cancer, inflammation, neurological disorders, among others.
CL2016000468A1 (en) Anti-dll3 conjugates (ligand3 delta type) manipulated and methods of use.
DOP2015000274A (en) CHEMICAL COMPOUNDS
DK3068392T3 (en) METHOD OF PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES
DK2961410T3 (en) USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K RELATED DISORDERS
CL2015000295A1 (en) Compounds derived from alkylpyrimidine; pharmaceutical composition that includes them; Use for the treatment of viral infections and other diseases.
CL2014001547A1 (en) Compounds derived from benzothienyl-pyrrolotriazine, such as protein tyrosine kinase inhibitors; preparation process of said compounds; pharmaceutical composition that includes them; and its use for the treatment and / or prevention of cancer and tumor diseases.
EP3030323A4 (en) Kdm1a inhibitors for the treatment of disease
CO6940374A2 (en) Compositions, uses and methods for the treatment of disorders and metabolic diseases
WO2014113089A3 (en) Signal-sensor polynucleotides for the alteration of cellular phenotypes
BR112014010206A2 (en) compound, pharmaceutical composition, use of compound, and method for the prophylaxis or treatment of a disease state or condition
CL2014001158A1 (en) Alkylated piperazine derivative compounds; pharmaceutical composition that includes them; process to prepare the pharmaceutical composition; kit and use in the treatment of immune disorders, cancer, cardiovascular diseases, inflammation, among others.
CL2012003415A1 (en) Compounds derived from 2-oxo-piperidine and 1,1-dioxide-thiazine, mdm2 inhibitors; pharmaceutical composition that includes them; and its use for the treatment of cancer.
BR112014010177A2 (en) compound, pharmaceutical composition, use of the compound, and method for the prophylaxis or treatment of a disease state or condition
HK1220324A1 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
BR112014010179A2 (en) compound, pharmaceutical composition, use of a compound, and method for the prophylaxis or treatment of a condition or condition
MX366317B (en) Compositions and methods for treating chronic inflammation and inflammatory diseases.
CL2014000849A1 (en) Compounds derived from substituted benzylindazoles, bub1 kinase inhibitors; manufacturing procedure; pharmaceutical composition; pharmaceutical combination; and its use in the treatment of hyperproliferative diseases.
ECSP16008797A (en) DERIVATIVES OF HETEROBICICLOARIL AS RORC2 INHIBITORS AND METHODS OF USE OF THE SAME
NI201500115A (en) ESTRA-1,3,5 (10), 16-TETRAENE-3-CARBOXAMIDES FOR THE INHIBITION OF 17B-HYDROXIESTEROID DEHYDROGENASE (AKR1 C3)